Prana looks at Huntington’s
Tuesday, 02 December, 2008
Melbourne company Prana Biotechnology is investigating the potential of its lead compound, PBT2, in Huntington’s disease.
PBT2, a metal-protein-attenuating compound (MPAC), is in Phase IIb clinical trials for Alzheimer’s disease.
The compound reduces the toxic metal-protein interaction seen in both neurological diseases and has a neuroprotective effect.
Chairman of Prana’s R&D advisory board, Professor Jeffery Cummings, told the company’s AGM that a report commissioned from an independent clinical research group recommended that Prana proceed to clinical trials.
Prana is in confidential talks with several pharma companies with a view to licensing PBT2, the company said.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
